The effects of reduced dose alemtuzumab for severe kidney transplant rejectio

• Conditions: transplantaat-afstoting; kidney transplant rejection; 10038430

• Registration Number: NL-OMON53625
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 25

Inclusion Criteria

In order to be eligible to participate in this study, a subject must meet all
of the following criteria:
- 18 years or older
- Treatment for severe or glucocorticoid-resistant kidney transplant rejection
with alemtuzumab.

Exclusion Criteria

A potential subject who meets any of the following criteria will be excluded
from participation in this study:
- Treatment with a different lymphocyte depleting agent (e.g. rATG) prior to
treatment with alemtuzumab for the same rejection episode.
- Recipients who have T cell counts below 200 × 106/L before the start of
therapy (for instance, because of lymphocyte depleting induction therapies).
- Inability to provide written informed consent

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified